Juli 2022: Enligt den senaste forskningen utförd av Emergen Research nådde den globala marknaden för CAR T-cellsterapi en storlek på 1.29 miljarder USD 2021 och förväntas registrera en intäkts-CAGR på 24.9 procent under prognosperioden. Den ökande förekomsten av cancer över hela världen samt den ökande dödligheten orsakad av cancer förväntas vara de primära drivkrafterna för intäktsökning på den globala marknaden för CAR-T-cellterapi under prognosperioden. Expansionen av kliniska prövningsaktiviteter i en rasande takt, spridningen av fusioner och förvärv och lockelsen av börsnoteringar är alla faktorer som bidrar till tillväxten av intäkter på den globala marknaden för CAR T-cellsterapi.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR T-Cell terapi market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR T-Cell terapi market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Ytterligare betydande resultat från rapporten tyder på det
År 2021, segmentet av diffusa stora B-celler lymfom was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with chimär antigenreceptor T-cellsterapi, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell non-Hodgkin lymfom who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
De nyckelföretag som för närvarande är verksamma på marknaden undersöks vidare i denna rapport, liksom deras företagsprofiler, produktportföljer, expansionsstrategier och strategiska allianser. Några exempel på dessa typer av allianser inkluderar fusioner och förvärv, samarbeten och joint ventures. Utöver detta ger den höjdpunkter om företagets prestationer och finansiella ställning, samt insikter om företagets marknadsräckvidd och globala position.
Företag profilerade på den globala marknaden för CAR T-Cell Therapy:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. och Eli Lilly and Company .
Läs mer om den globala CAR T-Cell Therapy-marknadsrapporten på: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
